How Important Is The U.S Market For Intuitive Surgical?
Leading surgical robot maker Intuitive Surgical (NYSE:ISRG) derives more than 70% of its revenues from the U.S. This is one key reason as to why Intuitive is largely safeguarded by foreign currency fluctuations in the emerging markets. In 2015, other medical device companies such as Abbott Labs (NYSE:ABT) and Boston Scientific (NYSE:BSX) witnessed significant decline in revenues due to currency headwinds in the emerging markets.
Although Intuitive saw an average revenue growth of 25% between 2008 and 2012, its sales growth in the U.S. was severely affected by negative reports related to the laparoscopic power morcellators in hysterectomy (removal of the uterus) and myomectomy (fibroids) procedures by the F.D.A. Going ahead, due to Intuitive’s high dependence on the U.S market, the company’s growth can be again limited by such reports. In the figure below, we illustrate how Intuitive’s revenues declined in the U.S. in 2013, due to negative reports by the F.D.A.
- Should You Pick Intuitive Surgical Stock At $370?
- Should You Pick Intuitive Surgical Stock At $375 After An Upbeat Q4?
- Is Intuitive Surgical Stock A Pick After A 9% Fall In A Month Amid Mixed Q3?
- Procedure Volume Growth To Drive Intuitive Surgical’s Q3
- With 2x Potential Returns Is DexCom A Better Pick Over Intuitive Surgical?
- Here’s What To Expect From Intuitive Surgical’s Q2
Have more questions about Intuitive Surgical? See the links below:
- What is Intuitive Surgical’s Revenue & Gross Profit Breakdown?
- What is Intuitive Surgical’s Fundamental Value based on Expected 2016 Results?
- By What Percentage Did Intuitive Surgical’s Revenue And Gross Profit Grow In The Last 5 Years?
Notes:
Global Large Cap | U.S. Mid & Small Cap | European Large & Mid Cap |More Trefis Research